[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 3, 2006

Adverse Events Related to Muraglitazar Use in Diabetes

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;295(17):1997-1998. doi:10.1001/jama.295.17.1997-a

To the Editor: The study of muraglitazar and adverse events by Dr Nissen and colleagues1 points out why physicians need hard outcomes data obtained in a blinded fashion before prescribing a new therapy for patients. The study, however, raises broader concerns beyond muraglitazar. Mortality data are needed prior to US Food and Drug Administration (FDA) approval for peroxisome proliferator–activated receptor (PPAR) agonists, and current practices that use combined therapy for patients with diabetes who have lipid abnormalities need to be examined.

First Page Preview View Large
First page PDF preview
First page PDF preview
×